.svg){kind=icon}
.svg){kind=icon}
.png)
.svg){kind=icon}
AHFS Drug Information®
An Evidence-based Foundation for Safe and Effective Drug Therapy
.jpg)
Title Details
2024 Ed.
2024 © American Society of Health-System Pharmacists®
ISBN-13: 978-1-58528-721-5
Pharmacy/Pharmacology, Dermatology, Disaster Medicine
Additional Details
2020, 2021, 2022, 2023 Doody's Core Titles List Selection I 5-Star Rating from Doody's Review Service
AHFS DI is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients.
Benefits that are unique to AHFS DI include:
- • The only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.
- • The only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization.
2024 Edition Updates
- • Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
- • Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
- • Contemporary topics such as new RSV treatments and vaccines, safety issues associated with glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
- • Inclusion of MedWatch alerts, Standardize4Safety information, REMS data, and focused FDA updates for various medications
- • Expanded content on new and emerging gene therapies
- • Updates to a variety of vaccine monographs including the pneumococcal, influenza, rabies, and COVID-19 mRNA vaccines
- • Expanded content on off-label uses, real-world data, and long-term clinical data
- • New content on over 175 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 190 medications
This title updates: Monthly
Similar Resources
The Power of A Digital Library
TDS Health titles provide the latest healthcare information in a customizable and convenient format. STAT!Ref goes where you go, accessible by desktop, laptop, wireless or web-enabled mobile devices. Harness the power of learning in you hands.
